Therefore, suitable TLR adjuvants, such as TLR5 adjuvant flagellin or TLR9 adjuvant CpG, could be incorporated into the genome of the novel MVA-based COVID-19 vaccine candidates. This evidence concerns the gene TLR5 and COVID-19.